Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05055258 · ClinicalTrials.gov registry record · Phase 2
A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II
A Phase 2 study, sponsored by KalVista Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT05055258: Clinical Trial Phase 2 study, sponsored by KalVista Pharmaceuticals.
NCT05055258 is a Phase 2 study that was terminated before completion, run by KalVista Pharmaceuticals. The registered enrollment target is 33 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05055258, a Phase 2 study, was terminated before completion, sponsored by KalVista Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
A study to assess whether different doses of KVD824 are effective in preventing attacks of Hereditary Angiodedema Type I or Type II.
Primary Outcome
To examine the number of investigator-confirmed attacks whilst on treatment compared to placebo. Given the early termination of the trial, there is insufficient enrollment to satisfy powering requirements.
Interventions
- DRUG KVD824
- DRUG Placebo to KVD824
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2021-11-18 |
| Est. Completion | 2022-10-27 |
| Phase | Phase 2 |
Why NCT05055258 stopped before completion
NCT05055258 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 2 interventions - of which KVD824 is the first listed.
NCT05055258 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05055258 about?
NCT05055258 is a clinical study titled "A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II". A study to assess whether different doses of KVD824 are effective in preventing attacks of Hereditary Angiodedema Type I or Type II.
What is the current status of trial NCT05055258?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2021-11-18. Estimated completion is 2022-10-27.
What interventions are being tested in trial NCT05055258?
The interventions under investigation include: KVD824 (DRUG), Placebo to KVD824 (DRUG).
Who is sponsoring clinical trial NCT05055258?
This trial is sponsored by KalVista Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05055258's enrollment target sits among peer trials
33 1553rd of 2000 higher than 438 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI